- Home
- RHI vs EXEL Comparison
RHI vs EXEL Comparison
Compare RHI & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RHI
- EXEL
- Stock Information
- Founded
- RHI 1948
- EXEL 1994
- Country
- RHI United States
- EXEL United States
- Employees
- RHI N/A
- EXEL N/A
- Industry
- RHI Professional Services
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RHI Consumer Discretionary
- EXEL Health Care
- Exchange
- RHI Nasdaq
- EXEL Nasdaq
- Market Cap
- RHI N/A
- EXEL 7.4B
- IPO Year
- RHI N/A
- EXEL 2000
- Fundamental
- Price
- RHI $67.23
- EXEL $29.06
- Analyst Decision
- RHI Hold
- EXEL Buy
- Analyst Count
- RHI 8
- EXEL 14
- Target Price
- RHI $70.63
- EXEL $29.43
- AVG Volume (30 Days)
- RHI 1.5M
- EXEL 2.0M
- Earning Date
- RHI 10-22-2024
- EXEL 10-29-2024
- Dividend Yield
- RHI 3.15%
- EXEL N/A
- EPS Growth
- RHI N/A
- EXEL 128.01
- EPS
- RHI 3.01
- EXEL 1.14
- Revenue
- RHI $5,985,165,000.00
- EXEL $2,013,976,000.00
- Revenue This Year
- RHI N/A
- EXEL $14.25
- Revenue Next Year
- RHI $5.04
- EXEL $0.48
- P/E Ratio
- RHI $22.33
- EXEL $25.44
- Revenue Growth
- RHI N/A
- EXEL 17.48
- 52 Week Low
- RHI $57.05
- EXEL $18.64
- 52 Week High
- RHI $88.39
- EXEL $29.75
- Technical
- Relative Strength Index (RSI)
- RHI 56.61
- EXEL 70.34
- Support Level
- RHI $66.19
- EXEL $26.06
- Resistance Level
- RHI $68.94
- EXEL $26.90
- Average True Range (ATR)
- RHI 1.13
- EXEL 0.81
- MACD
- RHI -0.07
- EXEL 0.32
- Stochastic Oscillator
- RHI 44.48
- EXEL 84.94
About EXEL Exelixis Inc.
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.